CHICAGO — At 2 years, crinecerfont demonstrated favorable effects on weight, body composition and insulin resistance in adults with congenital adrenal hyperplasia, researchers reported at ENDO 2026.
June 14, 2026
4 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026
Published Study Shows Clinically Significant Energy, Performance, and Metabolic Benefits of FutureCeuticals' Caffinity™
Endocrine Society Issues First Guideline on Central Precocious Puberty
Long-term use of crinecerfont reduced glucocorticoid dosage over 2 years and was tied to multiple improvements in clinical…
CHICAGO — Tirzepatide may impact how the body burns energy by activating brown adipose tissue, according to results of a small…
When comparing associations with mortality, combined creatinine-cystatin C assessment was more comparable to measured GFR than…
Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026
CHICAGO — Insulin resistance markers and BMI were more effective in detecting steatotic liver disease among adolescents and young…
CHICAGO — Garetosmab reduced new heterotopic bone lesions in patients with fibrodysplasia ossificans progressiva at 56 weeks…
